Inozyme Pharma, Inc. (INZY)

Inozyme Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-77.11	-71.17	-67.06	-56.62	-56.42	-19.72
Depreciation & Amortization	1.32	1.33	1.18	1.05	0.22	0.08
Share-Based Compensation	6.64	7.04	7.67	7.16	2.31	0.3
Other Operating Activities	-8.28	-7.87	0.45	0.26	17.93	0.53
Operating Cash Flow	-77.44	-70.68	-57.76	-48.15	-35.97	-18.81
Capital Expenditures	-0.16	-0.3	-0.41	-0.4	-0.57	-0.14
Change in Investments	-56.86	-53.35	-4.99	43.19	-116.61	-8.25
Investing Cash Flow	-57.02	-53.65	-5.4	42.8	-117.18	-8.39
Share Issuance / Repurchase	86.03	85.97	68.74	0.61	116.17	0.07
Debt Issued / Paid	20	40	4.05	0	0	0
Other Financing Activities	-	-	-	-	33.64	22.9
Financing Cash Flow	106.03	125.97	72.79	0.61	149.81	22.97
Exchange Rate Effect	-0.03	-0.02	-0.03	0.02	0	0
Net Cash Flow	-28.42	1.65	9.62	-4.75	-3.34	-4.23
Free Cash Flow	-77.59	-70.97	-58.17	-48.55	-36.54	-18.95
Free Cash Flow Per Share	-1.26	-1.37	-1.54	-2.06	-3.31	-16.02

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).